[Pubmed] Successful use of anti-CD19 CAR T cells in severe treatment-refractory stiff-person syndrome

[RSS-Bot]

Proc Natl Acad Sci U S A. 2024 Jun 25;121(26):e2403227121. doi: 10.1073/pnas.2403227121. Epub 2024 Jun 17.

ABSTRACT

Treatment with autologous chimeric antigen receptor (CAR) T cells has emerged as a highly effective approach in neuroimmunological disorders such as myasthenia gravis. We report a case of successful anti-CD19 CAR T cell use in treatment-refractory stiff-person syndrome (SPS). To investigate clinical and immunological effects of anti-CD19 CAR T cell use in treatment-refractory SPS, a 69-y-old female with a 9-y history of treatment-refractory SPS with deteriorating episodes of stiffness received an infusion of autologous anti-CD19 CAR T cells (KYV-101) and was monitored clinically and immunologically for more than 6 mo. CAR T cell infusion resulted in reduced leg stiffness, drastic improvement in gait, walking speed increase over 100%, and daily walking distance improvement from less than 50 m to over 6 km within 3 mo. GABAergic medication (benzodiazepines) was reduced by 40%. KYV-101 CAR T cells were well tolerated with only low-grade cytokine release syndrome. This report of successful use of anti-CD19 CAR T cells in treatment-refractory SPS supports continued exploration of this approach in SPS and other B cell-related autoimmune disorders.

PMID:38885382 | DOI:10.1073/pnas.2403227121


Source: https://pubmed.ncbi.nlm.nih.gov/3888538 ... t9+e462414